Cholesterol’s Hidden Geography: How Tumor Neighborhoods Fuel Resistant Prostate Cancer

When prostate cancer stops responding to hormone therapy, it enters a lethal phase known as castration-resistant prostate cancer, or CRPC. For decades, researchers have known that this transition involves profound metabolic rewiring, and cholesterol has repeatedly surfaced as a key player. Prostate cancer cells are notoriously dependent on lipids: they need cholesterol to build new membranes, to sustain signaling, and even to support the androgen receptor axis that drives tumor growth. Yet most studies have treated cholesterol metabolism as a uniform, whole-tumor property, measured in bulk tissue where individual cells and their microscopic neighborhoods blur together. A new study published in the Journal of Translational Medicine challenges that view, revealing that cholesterol metabolism in advanced prostate cancer is not just a systemic phenomenon but a spatially organized program, choreographed between tumor cells and the stromal cells that surround them.

The research, led by Sotaro Chikamatsu, Masaki Shiota, and colleagues at Kyushu University in collaboration with teams across Japan and the University of Tokyo, took a two-pronged approach. First, the investigators analyzed longitudinal clinical data from a prospective cohort of 199 patients with advanced prostate cancer, tracking how serum cholesterol changed as the disease evolved from a hormone-sensitive state to castration resistance. Second, they performed paired, single-cell-resolution spatial multi-omics analyses on hormone-sensitive prostate cancer specimens and matched CRPC samples taken from the very same patients. This paired design is a technical tour de force: rather than comparing tumors from different individuals, where genetic background and prior treatment histories confound the results, the researchers could observe how the metabolic landscape of a single patient’s tumor transformed as it adapted to androgen deprivation.

The clinical findings alone are striking. The team found that it was not the baseline level of serum total cholesterol that predicted risk, but rather the magnitude of its increase over time. Patients whose total cholesterol rose more steeply during treatment showed a significantly higher risk of progressing to CRPC. This distinction matters. Cholesterol is a routine clinical measurement, but it is usually interpreted as a static snapshot, a cardiovascular risk factor. Here, the data suggest that the trajectory, the dynamic change in circulating cholesterol, carries prognostic information about the tumor’s metabolic behavior. It hints at a biological dialogue in which the evolving tumor and the body’s lipid economy influence one another, with rising cholesterol levels marking, and possibly supporting, the tumor’s escape from hormone dependence.

To understand the tissue-level mechanisms behind this clinical signal, the researchers turned to spatial multi-omics, a family of technologies that maps gene expression and protein markers onto intact tissue sections at single-cell resolution. Using a targeted spatial transcriptomics platform profiling hundreds of curated genes, combined with multiplex immunofluorescence imaging, the team dissected both the malignant epithelial compartment and the surrounding tumor microenvironment, including macrophages, fibroblasts, and other stromal populations. Formalin-fixed, paraffin-embedded archival tissue, the standard material stored in hospital pathology labs, could thus be interrogated with unprecedented molecular depth while preserving the crucial dimension of location: knowing not just which cells express which genes, but which cells sit next to which.

What emerged was a picture of remarkable heterogeneity. Within the same tumor, the researchers identified distinct cholesterol acquisition strategies among cancer cells. Some tumor cells adopted an import-dominant program, ramping up expression of the scavenger receptor class B type 1, known as SCARB1, a cell-surface receptor that takes up cholesterol from circulating lipoproteins. Others favored de novo synthesis, building cholesterol from scratch through the mevalonate pathway. These metabolic subtypes were not randomly distributed. Instead, the spatial analyses revealed that import-dominant tumor cells showed a striking tendency to localize in close proximity to stromal cells with active cholesterol efflux programs, a spatial association that held across the paired HSPC-to-CRPC comparison and became more pronounced as the disease progressed.

The efflux-active stromal populations were themselves a discovery. The team identified expanded populations of macrophages characterized by high expression of ABCA1, the ATP-binding cassette transporter that pumps cholesterol out of cells, and fibroblasts marked by high expression of ABCA8, a related transporter associated with lipid handling. Macrophages are well known elsewhere in the body as cholesterol shuttlers; in atherosclerotic plaques, foam-cell macrophages loaded with cholesterol use ABCA1 to offload their lipid cargo. The new study suggests that an analogous lipid-handling program operates within the prostate tumor microenvironment, where macrophages and fibroblasts enriched for efflux machinery accumulate near tumor cells that are simultaneously upregulating cholesterol import. The spatial logic is compelling: stromal cells that export cholesterol could create a local lipid-rich niche, and tumor cells positioned nearby, equipped with SCARB1 and other import machinery, would be ideally placed to harvest it.

This model reframes the tumor microenvironment as a metabolic marketplace. Rather than viewing stromal cells as passive bystanders or merely as sources of growth factors, the study positions them as active participants in the tumor’s lipid supply chain. The coordinated geography, efflux-active macrophages and fibroblasts clustered around import-hungry cancer cells, is exactly the pattern one would expect if cholesterol were being transferred across the tumor-stroma interface. The researchers support this interpretation with enrichment analyses showing that the genes upregulated in ABCA1-high macrophages and ABCA8-high fibroblasts are significantly associated with cholesterol efflux-related biological processes, and with correlations between transporter expression and lipid-associated markers within the tissue. While such spatial associations demonstrate correlation rather than direct transport, the consistency of the pattern across patients and disease states makes a functional relationship highly plausible.

The implications for therapy are considerable. Current strategies targeting cholesterol in prostate cancer remain investigational, and one reason they have struggled is that tumors can compensate: block uptake, and cells may simply synthesize more; inhibit synthesis, and they may import instead. The spatial framework developed here suggests a more nuanced target. If import-dominant tumor cells depend on their efflux-active stromal partners, then disrupting the tumor-stroma metabolic coupling, rather than tumor cholesterol handling in isolation, might undermine the adaptation more effectively. It also raises the possibility that the stromal efflux programs themselves could serve as biomarkers, identifying patients whose tumors are primed for lipid scavenging and who might benefit most from metabolic interventions. The authors are appropriately cautious, framing these as potential therapeutic opportunities for future investigation rather than immediate clinical recommendations.

The study also carries a broader methodological message for cancer research. Bulk omics, which average molecular signals across millions of cells, would have averaged away the very phenomenon at the heart of this discovery. Only by preserving spatial context, and by pairing samples from the same patient before and after castration resistance emerged, could the team detect the coordinated choreography of cholesterol programs. As spatial transcriptomics and multiplex imaging become more accessible, similar metabolic geographies are likely to be uncovered in other cancers, where nutrient sharing between malignant and stromal cells is increasingly recognized as a hallmark of tumor ecology. The Japanese consortium’s work, conducted under the KYUCOG-1401 prospective trial framework with appropriate ethical oversight and patient consent, demonstrates what is possible when rigorous clinical cohort design meets cutting-edge spatial technology.

For patients with advanced prostate cancer, the road from these findings to the clinic will take time, and the authors emphasize that their results define a framework rather than a treatment. But the conceptual shift is immediate and profound. Castration-resistant prostate cancer is not simply a tumor that has learned to grow without androgens; it is a restructured ecosystem in which metabolic roles are divided among cell types and organized in space. Rising serum cholesterol during therapy, once dismissed as an incidental laboratory value, now appears as a potential echo of that restructuring, a systemic signature of a local metabolic bargain being struck between cancer cells and their neighbors. Decoding that bargain, and learning how to break it, may open one of the next frontiers in the treatment of this stubborn disease.

Subject of Research: Spatially organized cholesterol metabolism between tumor and stromal cells in castration-resistant prostate cancer

Article Title: Spatial multi-omics reveal spatially coordinated cholesterol metabolic programs in castration-resistant prostate cancer

Article References: Chikamatsu, S., Shiota, M., Fukuchi, G., Tanegashima, T., Seki, M., Kanai, A., Suzuki, Y., Matsuyama, H., Kamoto, T., Enokida, H., Fujimoto, N., Sakai, H., Igawa, T., Kamba, T., Yokomizo, A., Naito, S., & Eto, M. (2026). Spatial multi-omics reveal spatially coordinated cholesterol metabolic programs in castration-resistant prostate cancer. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08816-5

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08816-5

Keywords: prostate cancer, castration-resistant prostate cancer, spatial multi-omics, cholesterol metabolism, tumor microenvironment, metabolic reprogramming, SCARB1, ABCA1, ABCA8, macrophages, cancer-associated fibroblasts, spatial transcriptomics